Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS

Advances in Biological Regulation

Volumn 53, Issue 1, 2013, Pages 2-7

  Follo, Matilde Y ^a   Marmiroli, Sandra ^b   Faenza, Irene ^a   Fiume, Roberta ^a   Ramazzotti, Giulia ^a   Martelli, Alberto M ^a   Gobbi, Pietro ^c   McCubrey, James A ^d   Finelli, Carlo ^a   Manzoli, Francesco A ^a   Cocco, Lucio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF URBINO   (Italy)

^d EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874007797     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2012.09.009     Document Type: Review

References (50)

1. Bejar R., Levine R., Ebert B.L. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011, 29:504-515.
2. Cocco L., Follo M.Y., Faenza I., Fiume R., Ramazzotti G., Weber G., et al. Physiology and pathology of nuclear phospholipase C beta1. Adv Enzyme Regul 2011, 51:2-12.
3. Cooper A.B., Sawai C.M., Sicinska E., Powers S.E., Sicinski P., Clark M.R., et al. A unique function for cyclin D3 in early B cell development. Nat Immunol 2006, 7:489-497.
4. Cortelezzi A., Colombo G., Pellegrini C., Silvestris I., Moronetti Mazzeo L., Bosari S., et al. Bone marrow glycophorin-positive erythroid cells of myelodysplastic patients responding to high-dose rHuEPO therapy have a different gene expression pattern from those of nonresponders. Am J Hematol 2008, 83:531-539.
5. Daskalakis M., Nguyen T.T., Nguyen C., Guldberg P., Kohler G., Wijermans P., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 2002, 100:2957-2964.
6. di Giacomo V., Matteucci A., Stellacci E., Battistini A., Di Baldassarre A., Capitani S., et al. Expression of signal transduction proteins during the differentiation of primary human erythroblasts. J Cell Physiol 2005, 202:831-838.
7. Elliott S. Erythropoiesis-stimulating agents. Cancer Treat Res 2011, 157:55-74.
8. Faenza I., Matteucci A., Bavelloni A., Marmiroli S., Martelli A.M., Gilmour R.S., et al. Nuclear PLCbeta(1) acts as a negative regulator of p45/NF-E2 expression levels in Friend erythroleukemia cells. Biochim Biophys Acta 2002, 1589:305-310.
9. Faenza I., Matteucci A., Manzoli L., Billi A.M., Aluigi M., Peruzzi D., et al. A role for nuclear phospholipase Cbeta 1 in cell cycle control. J Biol Chem 2000, 275:30520-30524.
10. Faenza I., Ramazzotti G., Bavelloni A., Fiume R., Gaboardi G.C., Follo M.Y., et al. Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter. Endocrinology 2007, 148:1108-1117.
11. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The lancet oncology 2009, 10:223-232.
12. Fenaux P., Raza A., Mufti G.J., Aul C., Germing U., Kantarjian H., et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 2007, 109:4158-4163.
13. Fiume R., Ramazzotti G., Teti G., Chiarini F., Faenza I., Mazzotti G., et al. Involvement of nuclear PLCbeta1 in lamin B1 phosphorylation and G2/M cell cycle progression. FASEB J 2009, 23:957-966.
14. Follo M.Y., Faenza I., Fiume R., Ramazzotti G., McCubrey J.A., Martelli A.M., et al. Revisiting nuclear phospholipase C signalling in MDS. Adv Enzyme Regul 2011.
15. Follo M.Y., Finelli C., Bosi C., Martinelli G., Mongiorgi S., Baccarani M., et al. PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. Leukemia 2008, 22:198-200.
16. Follo M.Y., Finelli C., Mongiorgi S., Clissa C., Bosi C., Testoni N., et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A 2009, 106:16811-16816.
17. Follo M.Y., Finelli C., Mongiorgi S., Clissa C., Chiarini F., Ramazzotti G., et al. Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. Leukemia 2011, 25:271-280.
18. Follo M.Y., Mongiorgi S., Bosi C., Cappellini A., Finelli C., Chiarini F., et al. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res 2007, 67:4287-4294.
19. Follo M.Y., Mongiorgi S., Clissa C., Paolini S., Martinelli G., Martelli A.M., et al. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients. Leukemia 2012.
20. Follo M.Y., Russo D., Finelli C., Mongiorgi S., Clissa C., Fili C., et al. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. Leukemia 2012, 26:943-950.
21. Furukawa Y. Cell cycle control genes and hematopoietic cell differentiation. Leuk Lymphoma 2002, 43:225-231.
22. Garcia-Manero G. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011, 86:490-498.
23. Griffiths E.A., Gore S.D. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Seminars in hematology 2008, 45:23-30.
24. Jabbour E., Kantarjian H.M., Koller C., Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 2008, 112:1089-1095.
25. Kaminskas E., Farrell A., Abraham S., Baird A., Hsieh L.S., Lee S.L., et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005, 11:3604-3608.
26. Kerbauy D.B., Deeg H.J. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 2007, 35:1739-1746.
27. Kurtin S.E., Demakos E.P., Hayden J., Boglione C. Treatment of myelodysplastic syndromes. Clin J Oncol Nurs 2012, 16:23-35.
28. Lidonnici M.R., Corradini F., Waldron T., Bender T.P., Calabretta B. Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis. Blood 2008, 111:4771-4779.
29. Lindsley R.C., Ebert B.L. Molecular pathophysiology of myelodysplastic syndromes. Annu Rev Pathol 2012.
30. Lyons R.M. Myelodysplastic syndromes: therapy and outlook. Am J Med 2012, 125:S18-S23.
31. Maraldi T., Bertacchini J., Benincasa M., Guida M., De Pol A., Liotta L.A., et al. Reverse-phase protein microarrays (RPPA) as a diagnostic and therapeutic guide in multidrug resistant leukemia. Int J Oncol 2011, 38:427-435.
32. Marmiroli S., Ognibene A., Bavelloni A., Cinti C., Cocco L., Maraldi N.M. Interleukin 1 alpha stimulates nuclear phospholipase C in human osteosarcoma SaOS-2 cells. J Biol Chem 1994, 269:13-16.
33. Marshall A.J., Niiro H., Yun T.J., Clark E.A. Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase Cgamma pathway. Immunol Rev 2000, 176:30-46.
34. Martelli A.M., Evangelisti C., Chappell W., Abrams S.L., Basecke J., Stivala F., et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011, 25:1064-1079.
35. Martelli A.M., Gilmour R.S., Bertagnolo V., Neri L.M., Manzoli L., Cocco L. Nuclear localization and signalling activity of phosphoinositidase C beta in Swiss 3T3 cells. Nature 1992, 358:242-245.
36. Marzo F., Lavorgna A., Coluzzi G., Santucci E., Tarantino F., Rio T., et al. Erythropoietin in heart and vessels: focus on transcription and signalling pathways. J Thromb Thrombolysis 2008, 26:183-187.
37. Missiroli S., Etro D., Buontempo F., Ye K., Capitani S., Neri L.M. Nuclear translocation of active AKT is required for erythroid differentiation in erythropoietin treated K562 erythroleukemia cells. Int J Biochem Cell Biol 2009, 41:570-577.
38. Morgan M.A., Reuter C.W. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias. Ann Hematol 2006, 85:139-163.
39. Morris J.F., Rauscher F.J., Davis B., Klemsz M., Xu D., Tenen D., et al. The myeloid zinc finger gene, MZF-1, regulates the CD34 promoter in vitro. Blood 1995, 86:3640-3647.
40. Musto P., Maurillo L., Spagnoli A., Gozzini A., Rivellini F., Lunghi M., et al. Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program. Cancer 2010, 116:1485-1494.
41. Nyakern M., Tazzari P.L., Finelli C., Bosi C., Follo M.Y., Grafone T., et al. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia 2006, 20:230-238.
42. Park S., Chapuis N., Bardet V., Tamburini J., Gallay N., Willems L., et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 2008, 22:1698-1706.
43. Perl A.E., Kasner M.T., Tsai D.E., Vogl D.T., Loren A.W., Schuster S.J., et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 2009, 15:6732-6739.
44. Quintas-Cardama A., Tong W., Kantarjian H., Thomas D., Ravandi F., Kornblau S., et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 2008, 22:965-970.
45. Raj K., John A., Ho A., Chronis C., Khan S., Samuel J., et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007, 21:1937-1944.
46. Sekeres M.A., Maciejewski J.P., Giagounidis A.A., Wride K., Knight R., Raza A., et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008, 26:5943-5949.
47. Silverman L.R. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist 2001, 6(Suppl. 5):8-14.
48. Silverman L.R., Mufti G.J. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat Clin Pract Oncol 2005, 2(Suppl. 1):S12-S23.
49. Suh P.G., Park J.I., Manzoli L., Cocco L., Peak J.C., Katan M., et al. Multiple roles of phosphoinositidespecific phospholipase C isozymes. BMB Rep 2008, 41:415-434.
50. Wang Y., Wu J., Wang Z. Akt binds to and phosphorylates phospholipase C-gamma1 in response to epidermal growth factor. Mol Biol Cell 2006, 17:2267-2277.